187 related articles for article (PubMed ID: 33626863)
1. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Kornauth C; Herbaux C; Boidol B; Guillemette C; Caron P; Mayerhöfer ME; Poulain S; Tournilhac O; Pemovska T; Chong SJF; Van der Kouwe E; Kazianka L; Hopfinger G; Heintel D; Jäger R; Raderer M; Jäger U; Simonitsch-Klupp I; Sperr WR; Kubicek S; Davids MS; Staber PB
Haematologica; 2021 Aug; 106(8):2251-2256. PubMed ID: 33626863
[No Abstract] [Full Text] [Related]
2. Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Herling M; Dearden C; Zaja F; El-Sharkawi D; Ding W; Bellido M; Khot A; Tick L; Jacobsen E; Eyre TA; Roos-Weil D; Kadia T; Lucchini E; Pflug N; Davids MS; Pena G; Mukherjee N; Badawi M; Vizkelety T; Staber PB
Blood Adv; 2024 Feb; 8(4):842-845. PubMed ID: 38190628
[No Abstract] [Full Text] [Related]
3. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).
Alfayez M; Thakral B; Jain P; Ravandi F; Ferrajoli A; Jain N; Pemmaraju N; Wierda W; Kadia T
Leuk Lymphoma; 2020 Feb; 61(2):445-449. PubMed ID: 31566032
[No Abstract] [Full Text] [Related]
4. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Svanberg R; Ostrowski SR; Nasserinejad K; Kersting S; Dobber JA; Mattson M; Tran HTT; Levin MD; Mous R; Kater AP; Niemann CU
Leuk Lymphoma; 2020 Dec; 61(14):3422-3431. PubMed ID: 32865439
[TBL] [Abstract][Full Text] [Related]
5. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Hampel PJ; Rabe KG; Call TG; Ding W; Leis JF; Kenderian SS; Muchtar E; Wang Y; Koehler AB; Parrondo R; Schwager SM; Shi M; Braggio E; Slager SL; Kay NE; Parikh SA
Br J Haematol; 2022 Oct; 199(2):239-244. PubMed ID: 35841338
[TBL] [Abstract][Full Text] [Related]
6. Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
O'Brien SM
Clin Adv Hematol Oncol; 2021 Oct; 19(10):636-638. PubMed ID: 34637429
[No Abstract] [Full Text] [Related]
7. B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax.
Christoforidou A; Bezirgiannidou Z; Vrachiolias G; Papoutselis M; Spanoudakis E; Kotsianidis Ι
Leuk Lymphoma; 2020 Mar; 61(3):749-752. PubMed ID: 31713446
[No Abstract] [Full Text] [Related]
8. Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
Ferrarini I; Gandini F; Zapparoli E; Rigo A
Curr Oncol; 2022 Apr; 29(4):2792-2797. PubMed ID: 35448201
[TBL] [Abstract][Full Text] [Related]
9. Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
Andersen MA; Valentin R; Dissing Sjö L; Borgwardt L; Schmiegelow K; Andersen MK; Marvig RL; Yde CW; Niemann CU
Acta Oncol; 2020 Dec; 59(12):1547-1551. PubMed ID: 32970500
[No Abstract] [Full Text] [Related]
10. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
[No Abstract] [Full Text] [Related]
12. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Lu P; Wang S; Franzen CA; Venkataraman G; McClure R; Li L; Wu W; Niu N; Sukhanova M; Pei J; Baldwin DA; Nejati R; Wasik MA; Khan N; Tu Y; Gao J; Chen Y; Ma S; Larson RA; Wang YL
Blood Cancer J; 2021 Feb; 11(2):39. PubMed ID: 33602908
[TBL] [Abstract][Full Text] [Related]
13. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
14. Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
Leitinger EJ; Wright RM; Nelson N; Anderson MA; Juneja S
Pathology; 2021 Dec; 53(7):926-929. PubMed ID: 33947523
[No Abstract] [Full Text] [Related]
15. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
[TBL] [Abstract][Full Text] [Related]
18. Risk/benefit of BTK/venetoclax combos: the context matters!
Seymour JF
Blood; 2024 Feb; 143(7):563-564. PubMed ID: 38358849
[No Abstract] [Full Text] [Related]
19. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.
Kater AP; Slinger E; Cretenet G; Martens AW; Balasubramanian S; Leverson JD; Eldering E
Blood Adv; 2021 Dec; 5(23):5410-5414. PubMed ID: 34555843
[TBL] [Abstract][Full Text] [Related]
20. Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
Roulin L; Haioun C; Lemonnier F
Ann Hematol; 2021 May; 100(5):1345-1347. PubMed ID: 33655374
[No Abstract] [Full Text] [Related]
[Next] [New Search]